A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150)

JW Mellors, GJ Im, E Tramontano, SR Winkler, DJ Medina, GE Dutschman, HZ Bazmi, G Piras, CJ Gonzalez and YC Cheng

Department of Internal Medicine, University of Pittsburgh Medical Center, Pennsylvania.

Tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione (TIBO) derivatives (e.g., R82150) are potent, human immunodeficiency virus-1 (HIV-1)-specific, inhibitors of reverse transcriptase (RT) that are undergoing initial evaluation in clinical trials. Because HIV-1 has become resistant to other RT inhibitors, we investigated the potential for viral resistance to TIBO R82150 by serial in vitro passage of HIV- 1IIIB in the presence of drug. R82150-resistant variants (> 100-fold increase in IC50) dominated the replicating virus population after only three or four passages. R82150-resistant virus was partially cross- resistant to other HIV-1-specific RT inhibitors, including nevirapine (approximately 10-fold increase in IC50) and 1-[(2- hydroxyethoxy)methyl]-6-(phenylthio)thymine (approximately 3.5-fold increase) but remained susceptible to 2',3'-dideoxynucleosides and phosphonoformate. DNA sequencing of cloned resistant RT, combined with site-specific mutational analyses and construction of mutant recombinant proviruses, demonstrated that a single, conservative amino acid substitution (Leu100 to Ile) in HIV-1 RT is responsible for high level R82150 resistance and partial nevirapine resistance. These studies indicate that a subtle mutation in HIV-1 RT can dramatically affect viral susceptibility to an HIV-1-specific RT inhibitor. The clinical efficacy of TIBO derivatives and other HIV-1-specific RT inhibitors may be limited by the emergence of drug-resistant viral strains.

Volume 43, Issue 1, pp. 11-16, 01/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				H. Z. Bazmi, J. L. Hammond, S. C. H. Cavalcanti, C. K. Chu, R. F. Schinazi, and J. W. Mellors In Vitro Selection of Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Decrease Susceptibility to (-)-beta -D-Dioxolane-Guanosine and Suppress Resistance to 3'-Azido-3'-Deoxythymidine Antimicrob. Agents Chemother., July 1, 2000; 44(7): 1783 - 1788. [Abstract] [Full Text]

				D. V. Nissley, P. L. Boyer, D. J. Garfinkel, S. H. Hughes, and J. N. Strathern Hybrid Ty1/HIV-1 elements used to detect inhibitors and monitor the activity of HIV-1 reverse transcriptase PNAS, November 10, 1998; 95(23): 13905 - 13910. [Abstract] [Full Text] [PDF]

				R. Spence, W. Kati, K. Anderson, and K. Johnson Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors Science, February 17, 1995; 267(5200): 988 - 993. [Abstract] [PDF]